Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: The role of Rad51

Breast

Volumn 22, Issue 6, 2013, Pages 1178-1183

  Sosińska Mielcarek, Katarzyna ^a   Duchnowska, Renata ^b   Winczura, Piotr ^c   Badzio, Andrzej ^c   Majewska, Hanna ^d   Lakomy, Joanna ^d   Peksa, Rafał ^d   Pieczyńska, Beata ^d   Radecka, Barbara ^e   Debska, Sylwia ^f   Biernat, Wojciech ^d   Jassem, Jacek ^d  

^a Regional Oncology Center   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c Regional Hospital   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e Regional Oncology Center   (Poland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Brain metastases; Breast cancer; Estrogen receptor; HER2; Ki 67; Rad51

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; CLAUDIN 3; CLAUDIN 4; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; RAD51 PROTEIN; UVOMORULIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POLAND; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY;

BRAIN METASTASES; BREAST CANCER; ESTROGEN RECEPTOR; HER2; KI-67; RAD51;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLAUDIN-3; CLAUDIN-4; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; KI-67 ANTIGEN; MIDDLE AGED; RAD51 RECOMBINASE; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, CXCR4; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84887150208     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.08.011     Document Type: Article

References (29)

1. Frisk G., Svensson T., Bäcklund L.M., Lidbrink E., Blomqvist P., Smedby K.E. Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer 2012, 106:1850-1853.
2. Crivellari D., Pagani O., Veronesi A., Lombardi D., Nolè F., Thürlimann B., et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001, 12:353-356.
3. Carey L.A., Ewend M.G., Metzger R., Sawyer L., Dees E.C., Sartor C.I., et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 2004, 88:273-280.
4. Duchnowska R., Dziadziuszko R., Czartoryska-Arłukowicz B., Radecka B., Szostakiewicz B., Sosińska-Mielcarek K., et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009, 117:297-303.
5. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
6. Smid M., Wang Y., Zhang Y., Jiang J., Sieuwerts A.M., Smid M., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68:3108-3114.
7. Maki D.D., Grossman R.I. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 2000, 21:1064-1066.
8. Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006, 30:1097-1104.
9. Da Silva L., Simpson P.T., Smart C.E., Cocciardi S., Waddell N., Lane A., et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 2010, 12:R46.
10. Lee B.C., Lee T.H., Avraham S., Avraham H.K. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2004, 2:327-338.
11. Duchnowska R., Biernat W., Szostakiewicz B., Sperinde J., Piette F., Haddad M., et al. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist 2012, 17:26-35.
12. Andre F., Cabioglu N., Assi H., Sabourin J.C., Delaloge S., Sahin A., et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006, 17:945-951.
13. Schmid B.C., Rezniczek G.A., Fabjani G. e Yoneda T, Leodolter S, Zeillinger R. The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat 2007, 106:333-342.
14. Mendes O., Kim H.T., Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 2005, 22:237-246.
15. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
16. Harrell J.C., Prat A., Parker J.S., Fan C., He X., Carey L., et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 2012, 132:523-535.
17. Duchnowska R., Jassem J., Pankaj Goswami C., Gokmen-Polar Y., Li L., Thorat M.A., et al. 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. J Clin Oncol 2012, 30(Suppl):8s.
18. Brogi E., Murphy C.G., Johnson M.L., Conlin A.K., Hsu M., Patil S., et al. Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Ann Oncol 2011, 22:2597-2603.
19. Pestalozzi B.C., Zahrieh D., Price K.N., Holmberg S.B., Lindtner J., Collins J., et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17:935-944.
20. Graesslin O., Abdulkarim B.S., Coutant C., Huguet F., Gabos Z., Hsu L., et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 2010, 28:2032-2037.
21. Guiu S., Michiels S., André F., Cortes J., Denkert C., Di Leo A., et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker?. Ann Oncol 2012, 23:2997-3006.
22. Stuart-Harris R., Caldas C., Pinder S.E., Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17:323-334.
23. Chang J., Ormerod M., Powles T.J., Allred D.C., Ashley S.E., Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000, 89:2145-2152.
24. Shao M.M., Liu J., Vong J.S. A subset of breast cancer predisposes to brain metastasis. Med Mol Morphol 2011, 44:15-20.
25. Raderschall E., Stout K., Freier S., Suckow V., Schweiger S., Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002, 62:219-225.
26. Vispé S., Cazaux C., Lesca C., Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998, 26:2859-2864.
27. Henning W., Stürzbecher H.W. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003, 193:91-109.
28. Gildemeister O.S., Sage J.M., Knight K.L. Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C. J Biol Chem 2009, 284:31945-31952.
29. Tarsounas M., Davies D., West S.C. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 2003, 22:1115-1123.